Brief: Enanta Pharma Presents Preclinical Data For Its Respiratory Syncytial Virus And Human Metapneumovirus Programs At 12th International RSV Symposium
29/09/2022 12:43
Sept 29 (Reuters) - Enanta Pharmaceuticals Inc ENTA.O :
* ENANTA PHARMACEUTICALS PRESENTS PRECLINICAL DATA FOR ITS
RESPIRATORY SYNCYTIAL VIRUS (RSV) AND HUMAN METAPNEUMOVIRUS
(HMPV) PROGRAMS AT 12TH INTERNATIONAL RSV SYMPOSIUM
* ENANTA PHARMACEUTICALS - EDP-323 DEMONSTRATES POTENT
INHIBITION
OF RSV REPLICATION AND ASSOCIATED PATHOLOGY
* ENANTA PHARMACEUTICALS INC - 3D AIRWAY MODEL PROVIDES
ACCURATE
INSIGHT INTO DYNAMICS OF RSV INFECTION
* ENANTA PHARMACEUTICALS - ADVANCES IN HMPV VIROLOGY METHODS
IMPROVE IN VITRO CHARACTERIZATION OFDIRECT-ACTING ANTIVIRALS
Source text for Eikon: ID:nBw2W7b8Sa
Further company coverage: ENTA.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Enanta Pharmaceuticals
See all newsEnanta Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Enanta Pharmaceuticals Q3 revenue misses estimates, hurt by lower royalties
Enanta Pharmaceuticals Inc expected to post a loss of 51 cents a share - Earnings Preview
Enanta Pharma Q2 loss narrows on higher AbbVie royalties, lower costs
Enanta Pharmaceuticals Q1 revenue beats estimates